Filter Search


Healthcare and Medical


Location Summary Deadline
Germany Medicines Containing The Active Ingredient Leuprorelin (atc: L02ae02) 2026-11-30
Germany Medicines Containing The Active Ingredient Mesalazine (atc: A07ec02) 2026-11-30
Germany Medicines Containing The Active Ingredient Filgrastim (atc: L03aa02) 2026-11-30
Germany Medicines Containing The Active Ingredient Secukinumab (atc: L04ac10) 2026-11-30
Germany Medicines Containing The Active Ingredient Pyridostigmine (atc: N07aa02) 2026-11-30
Germany Conclusion Of Non-exclusive Discount Agreements Pursuant To Section 130a Paragraph 8/130c Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredient Acetylsalicylic Acid (b01ac06) Within The Framework Of A So-called Open-house Model. 2026-11-30
Germany Conclusion Of Non-exclusive Discount Agreements Pursuant To Section 130a Paragraph 8/130c Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredient Dornase Alfa (r05cb13) Within The Framework Of A So-called Open-house Model. 2026-11-30
Germany Conclusion Of Non-exclusive Discount Agreements Pursuant To Sections 130a Paragraph 8/130c Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredient Pegfilgrastim (l03aa13) Within The Framework Of A So-called Open House Model. 2026-11-30
Germany Conclusion Of Non-exclusive Discount Agreements Pursuant To Section 130a Paragraph 8/130c Paragraph 1 Social Security Code V For Medicinal Products Containing The Active Ingredient Acetylsalicylic Acid (b01ac06) Within The Framework Of A So-called Open Ho 2026-11-30
Germany Conclusion Of Non-exclusive Discount Agreements Pursuant To Sections 130a Paragraph 8/130c Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredient Peginterferon Beta1a (l03ab13) Within The Framework Of A So-called Open House Model. 2026-11-30
Whats app